News: CMS releases new codes for COVID-19 procedures

CMS is implementing 12 new ICD-10 procedure codes to identify new therapies for COVID-19.

These codes include:

• XW013F5 - Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
• XW033E5 - Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW033F5 - Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW033G5 - Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW033H5 - Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW043E5 - Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
• XW043F5 - Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
• XW043G5 - Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
• XW043H5 - Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
• XW0DXF5 - Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
• XW13325 - Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5
• XW14325 - Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5

The new codes are effective for discharges on or after August 1. The new codes will not affect the MS-DRG assignment.

Editor’s note: The new ICD-10 procedure codes can be found here.